MX2021000239A - Modificacion de moleculas de union para minimizar interacciones preexistentes. - Google Patents
Modificacion de moleculas de union para minimizar interacciones preexistentes.Info
- Publication number
- MX2021000239A MX2021000239A MX2021000239A MX2021000239A MX2021000239A MX 2021000239 A MX2021000239 A MX 2021000239A MX 2021000239 A MX2021000239 A MX 2021000239A MX 2021000239 A MX2021000239 A MX 2021000239A MX 2021000239 A MX2021000239 A MX 2021000239A
- Authority
- MX
- Mexico
- Prior art keywords
- binding molecules
- minimize
- minimize pre
- interactions
- modifying binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695988P | 2018-07-10 | 2018-07-10 | |
| PCT/US2019/041203 WO2020014358A1 (en) | 2018-07-10 | 2019-07-10 | Modifying binding molecules to minimize pre-existing interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000239A true MX2021000239A (es) | 2021-03-25 |
Family
ID=67544330
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000239A MX2021000239A (es) | 2018-07-10 | 2019-07-10 | Modificacion de moleculas de union para minimizar interacciones preexistentes. |
| MX2025013509A MX2025013509A (es) | 2018-07-10 | 2021-01-07 | Modificacion de moleculas de union para minimizar interacciones preexistentes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025013509A MX2025013509A (es) | 2018-07-10 | 2021-01-07 | Modificacion de moleculas de union para minimizar interacciones preexistentes |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11448651B2 (https=) |
| EP (1) | EP3820891A1 (https=) |
| JP (2) | JP7665339B2 (https=) |
| KR (1) | KR102938177B1 (https=) |
| CN (1) | CN112543768B (https=) |
| AR (1) | AR115730A1 (https=) |
| AU (1) | AU2019302642B2 (https=) |
| BR (1) | BR112020026784A2 (https=) |
| CA (1) | CA3104873A1 (https=) |
| EA (1) | EA202190228A1 (https=) |
| IL (2) | IL316308A (https=) |
| MX (2) | MX2021000239A (https=) |
| MY (1) | MY202673A (https=) |
| SG (1) | SG11202012835RA (https=) |
| TW (2) | TW202428612A (https=) |
| WO (1) | WO2020014358A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019302642B2 (en) | 2018-07-10 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Modifying binding molecules to minimize pre-existing interactions |
| US20260008857A1 (en) * | 2024-06-13 | 2026-01-08 | Flagship Pioneering Innovations Vi, Llc | Antigen Binding Molecules Targeting Interleukine-4 Receptor Subunit Alpha (IL-4Ra) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| US6056957A (en) * | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CA2644663A1 (en) | 2006-03-23 | 2007-09-27 | Kirin Pharma Kabushiki Kaisha | Agonist antibody to human thrombopoietin receptor |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| AU2008348252A1 (en) | 2008-01-15 | 2009-07-23 | Stichting Sanquin Bloedvoorziening | Method and kits for detecting antibodies against therapeutic antibodies |
| CN105218673A (zh) * | 2008-10-10 | 2016-01-06 | 新兴产品开发西雅图有限公司 | Tcr复合物免疫治疗剂 |
| CA2741114A1 (en) | 2008-10-24 | 2010-04-29 | Cornelis Lammert Verweij | Biomarkers for predicting the development of chronic autoimmune diseases |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| WO2010122148A1 (en) | 2009-04-24 | 2010-10-28 | Boehringer Ingelheim International Gmbh | An improved antibody domain and antibody fragments and antibodies based thereon |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| WO2011074965A1 (en) | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
| WO2012166588A2 (en) | 2011-06-01 | 2012-12-06 | Morehouse School Of Medicine | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| SG2014010482A (en) * | 2011-08-17 | 2014-04-28 | Glaxo Group Ltd | Modified proteins and peptides |
| TW201444872A (zh) | 2013-03-06 | 2014-12-01 | Merrimack Pharmaceuticals Inc | 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體 |
| TWI755763B (zh) * | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CA2950155C (en) | 2014-06-02 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| CN117442748A (zh) | 2014-10-02 | 2024-01-26 | 希望之城公司 | 多价中间表位、中间表位结合抗体及其用途 |
| BR112017004810A2 (pt) | 2014-11-05 | 2017-12-12 | Hoffmann La Roche | imunoensaio |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| AU2016344665C1 (en) * | 2015-10-29 | 2023-07-27 | F. Hoffmann-La Roche Ag | Anti-variant Fc-region antibodies and methods of use |
| US20170137535A1 (en) | 2015-10-30 | 2017-05-18 | Genentech, Inc. | Anti-factor d antibody formulations |
| BR112019004733A2 (pt) | 2016-09-19 | 2019-05-28 | Celgene Corp | métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1 |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| WO2019101863A1 (en) | 2017-11-22 | 2019-05-31 | Vacara Ab | Antibodies to citrullinated proteins |
| AU2019302642B2 (en) | 2018-07-10 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Modifying binding molecules to minimize pre-existing interactions |
| WO2020246891A1 (en) | 2019-06-07 | 2020-12-10 | Sanquin Innovatie B.V. | Methods and compounds for typing rheumatoid factors |
-
2019
- 2019-07-10 AU AU2019302642A patent/AU2019302642B2/en active Active
- 2019-07-10 CA CA3104873A patent/CA3104873A1/en active Pending
- 2019-07-10 AR ARP190101943A patent/AR115730A1/es unknown
- 2019-07-10 US US16/507,880 patent/US11448651B2/en active Active
- 2019-07-10 JP JP2020572773A patent/JP7665339B2/ja active Active
- 2019-07-10 KR KR1020217002619A patent/KR102938177B1/ko active Active
- 2019-07-10 WO PCT/US2019/041203 patent/WO2020014358A1/en not_active Ceased
- 2019-07-10 MX MX2021000239A patent/MX2021000239A/es unknown
- 2019-07-10 IL IL316308A patent/IL316308A/en unknown
- 2019-07-10 EA EA202190228A patent/EA202190228A1/ru unknown
- 2019-07-10 TW TW113110335A patent/TW202428612A/zh unknown
- 2019-07-10 TW TW108124293A patent/TWI838388B/zh active
- 2019-07-10 EP EP19749878.5A patent/EP3820891A1/en active Pending
- 2019-07-10 SG SG11202012835RA patent/SG11202012835RA/en unknown
- 2019-07-10 CN CN201980042886.7A patent/CN112543768B/zh active Active
- 2019-07-10 MY MYPI2020006898A patent/MY202673A/en unknown
- 2019-07-10 BR BR112020026784-8A patent/BR112020026784A2/pt unknown
-
2020
- 2020-12-27 IL IL279803A patent/IL279803A/en unknown
-
2021
- 2021-01-07 MX MX2025013509A patent/MX2025013509A/es unknown
-
2022
- 2022-09-19 US US17/933,185 patent/US12523659B2/en active Active
-
2025
- 2025-04-09 JP JP2025064335A patent/JP2025100662A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019302642A1 (en) | 2021-02-25 |
| EP3820891A1 (en) | 2021-05-19 |
| CN112543768A (zh) | 2021-03-23 |
| KR102938177B1 (ko) | 2026-03-11 |
| EA202190228A1 (ru) | 2021-04-14 |
| US12523659B2 (en) | 2026-01-13 |
| SG11202012835RA (en) | 2021-01-28 |
| CN112543768B (zh) | 2024-05-03 |
| AU2019302642B2 (en) | 2025-10-30 |
| US20200018754A1 (en) | 2020-01-16 |
| WO2020014358A1 (en) | 2020-01-16 |
| JP7665339B2 (ja) | 2025-04-21 |
| MY202673A (en) | 2024-05-14 |
| AR115730A1 (es) | 2021-02-17 |
| TW202428612A (zh) | 2024-07-16 |
| IL279803A (en) | 2021-03-01 |
| US11448651B2 (en) | 2022-09-20 |
| IL316308A (en) | 2024-12-01 |
| TWI838388B (zh) | 2024-04-11 |
| MX2025013509A (es) | 2025-12-01 |
| JP2021531245A (ja) | 2021-11-18 |
| CA3104873A1 (en) | 2020-01-16 |
| TW202021984A (zh) | 2020-06-16 |
| JP2025100662A (ja) | 2025-07-03 |
| US20230266333A1 (en) | 2023-08-24 |
| BR112020026784A2 (pt) | 2021-03-30 |
| KR20210030378A (ko) | 2021-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210326A (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
| PH12018500157A1 (en) | Antibody constructs for flt3 and cd3 | |
| SA519402463B1 (ar) | بولي ببتيدات رابطة لمستقبل ترانسفيرين معالجة بالهندسة الوراثية | |
| CR20170032A (es) | Moleculas biespecíficas de unión a antígeno activadoras de células t | |
| MX2020000957A (es) | Anticuerpos anti-sirp-alfa y metodos relacionados. | |
| CR20180162A (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
| PH12019502087A1 (en) | Anti-par2 antibodies and uses thereof | |
| PH12018500216A1 (en) | Antibody constructs for cd70 and cd3 | |
| MX2016017271A (es) | Moleculas con especificidad para cd45 y cd79. | |
| JO3788B1 (ar) | تراكيب جسم مضاد لـ egfrviii وcd3 | |
| MX2021008367A (es) | Constructos de anticuerpos para cdh19 y cd3. | |
| EA201490454A1 (ru) | Тернесит в качестве активатора для латентно-гидравлических и пуццолановых веществ | |
| UA108199C2 (uk) | АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ | |
| MX2019011759A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando el mismo. | |
| MX391238B (es) | Metodo y dispositivo para la verificacion de privilegios | |
| PH12019500551A1 (en) | Antibody specifically binding to il-17a and functional fragment thereof | |
| BR112018073945A2 (pt) | métodos para tratamento de miastenia grave generalizada refratária | |
| MY180940A (en) | Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor | |
| MX2025013509A (es) | Modificacion de moleculas de union para minimizar interacciones preexistentes | |
| MX2016014416A (es) | Anticuerpos anti-her3 que se unen a la horquilla beta de her3. | |
| MX2022006316A (es) | Composicion para la preparacion de alulosa y procedimiento para la preparacion de alulosa mediante el uso de la misma. | |
| MX2021004430A (es) | Proceso para producir (met-) acrilato de amonio. | |
| UA122791C2 (uk) | Антитіло до igf-1r та його застосування для діагностики раку | |
| EA201991922A1 (ru) | Сконструированные полипептиды, связывающие трансферриновый рецептор |